Increasing the effectiveness of psychodynamic short-term psychotherapy for anxiety disorders by adding elements of Emotion Focused Therapy: An open proof of concept trial

Not Applicable

Conditions: F41.0
Social phobias
Panic disorder [episodic paroxysmal anxiety]
F40.1
F41.1
Anxiety disorders: Social Phobia, Generalized anxiety disorder, Panic disorder/ Agoraphobia
F40.01
Generalized anxiety disorder

Registration Number: DRKS00013478

Lead Sponsor: Klinik für Psychosomatische Medizin und Psychotherapie; Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 20

Inclusion Criteria

Diagnosis of an Anxiety disorder (SP, Panic/Agoraphobia, GAD, SCID-I)
Anxiety disorder must be primary diagnosis (most severe disorder according to ADIS-IV)
Patients with anxiety disorders with comorbid disorders will be included, provided that the anxiety disorder is the primary diagnosis, thus ensuring a clinically representative sample
age: 18 to 70 years
Informed consent

Exclusion Criteria

psychotic disorder
prominent risk of self-harm
acute substance related disorders
personality disorders except for avoidant and dependent personality disorder (SCID-II)
Posttraumatic Stress Disorder (PTSD) and/or sexual abuse in childhood
organic mental disorder
severe medical conditions
concurrent psychotherapeutic treatment
psychopharmacological treatment (stable medical treatments (e.g. SSRI without dose adaptation are permitted)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Global Impression (CGI-scale) after treatment

Secondary Outcome Measures

Name	Time	Method
Secondary endpoints: Anxiety (Mobility index, MI, Body Sensations Questionnaire, BSQ, Agoraphobic Cognitions Questionnaire, ASQ, Liebowitz Social Anxiety Scale, LSAS, Penn State Worry Questionnaire, PSWQ), depression (PHQ-9), quality of life and social functioning (EQ-5D), distress (global severity index, SCL-90), Emotion regulation skills (SEK-27), resilience (RS-11), Working alliance (WAI-12R).<br>Therapists and patients will be asked for the feasibility and acceptance of the treatment (ZUF-8)<br>Safety: Description of serious adverse events and drop-outs<br>Assessments at baseline, after 8 sessions, after 16 sessions, and after 25 sessions (post-treatment), 3 months after end of treatment.